International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment


Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, et al. International Myeloma working group recommendations for the diagnosis and management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology [Internet]. 2016;34(13):1544 - 1557.


Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For themanagement of RI in patientswithmultiplemyeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with closemonitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance . 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance . 30 mL/min (grade A). © 2016 by American Society of Clinical Oncology.


Cited By :10Export Date: 18 February 2017References: Riccardi, A., Gobbi, P.G., Ucci, G., Changing clinical presentation of multiple myeloma (1991) Eur J Cancer, 27, pp. 1401-1405;Abbott, K.C., Agodoa, L.Y., Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival (2001) Clin Nephrol, 56, pp. 207-210; Tsakiris, D.J., Stel, V.S., Finne, P., Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERAEDTA Registry study (2010) Nephrol Dial Transplant, 25, pp. 1200-1206; Augustson, B.M., Begum, G., Dunn, J.A., Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002-medical research council adult leukaemia working party (2005) J Clin Oncol, 23, pp. 9219-9226; Dimopoulos, M.A., Delimpasi, S., Katodritou, E., Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents (2014) Ann Oncol, 25, pp. 195-200; Uttervall, K., Duru, A.D., Lund, J., The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment (2014) PLoS One, 9, p. e101819; Khan, R., Apewokin, S., Grazziutti, M., Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma (2015) Leukemia, 29, pp. 1195-1201; Atkins, D., Best, D., Briss, P.A., Grading quality of evidence and strength of recommendations (2004) BMJ, 328, p. 1490; Dimopoulos, M.A., Kastritis, E., Rosinol, L., Pathogenesis and treatment of renal failure in multiple myeloma (2008) Leukemia, 22, pp. 1485-1493; Hutchison, C.A., Batuman, V., Behrens, J., The pathogenesis and diagnosis of acute kidney injury in multiple myeloma (2012) Nat Rev Nephrol, 8, pp. 43-51; Kastritis, E., Terpos, E., Dimopoulos, M.A., Current treatments for renal failure due to multiple myeloma (2013) Expert Opin Pharmacother, 14, pp. 1477-1495; Huang, Z.Q., Sanders, P.W., Biochemical interaction between tamm-horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy (1995) Lab Invest, 73, pp. 810-817; Sengul, S., Zwizinski, C., Simon, E.E., Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells (2002) Kidney Int, 62, pp. 1977-1988; From, A.M., Bartholmai, B.J., Williams, A.W., Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: A retrospective cohort study of 7977 patients at Mayo Clinic (2008) Clin J Am Soc Nephrol, 3, pp. 10-18; Nasr, S.H., Valeri, A.M., Sethi, S., Clinicopathologic correlations in multiple myeloma: A case series of 190 patients with kidney biopsies (2012) Am J Kidney Dis, 59, pp. 786-794; Merlini, G., Bellotti, V., Molecular mechanisms of amyloidosis (2003) N Engl J Med, 349, pp. 583-596; Buxbaum, J., Gallo, G., Nonamyloidotic monoclonal immunoglobulin deposition disease. Lightchain, heavy-chain, and light- And heavy-chain deposition diseases (1999) Hematol Oncol Clin North Am, 13, pp. 1235-1248; Bridoux, F., Leung, N., Hutchison, C.A., Diagnosis of monoclonal gammopathy of renal significance (2015) Kidney Int, 87, pp. 698-711; Fermand, J.P., Bridoux, F., Kyle, R.A., How I treat monoclonal gammopathy of renal significance (MGRS) (2013) Blood, 122, pp. 3583-3590; Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., International myeloma working group updated criteria for the diagnosis of multiple myeloma (2014) Lancet Oncol, 15, pp. e538-e548; Masson, I., Flamant, M., Maillard, N., MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients (2013) Transplantation, 95, pp. 1211-1217; Inker, L.A., Schmid, C.H., Tighiouart, H., Estimating glomerular filtration rate from serum creatinine and cystatin C (2012) N Engl J Med, 367, pp. 20-29; Levey, A.S., Eckardt, K.U., Tsukamoto, Y., Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) (2005) Kidney Int, 67, pp. 2089-2100; Levey, A.S., Stevens, L.A., Schmid, C.H., A new equation to estimate glomerular filtration rate (2009) Ann Intern Med, 150, pp. 604-612; Michels, W.M., Grootendorst, D.C., Verduijn, M., Performance of the cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size (2010) Clin J Am Soc Nephrol, 5, pp. 1003-1009; Dimopoulos, M.A., Terpos, E., Symeonidis, A.S., Estimated glomerular filtration rate calculated by the CKD-EPI formula has improved prognostic ability over MDRD formula in patients with newly diagnosed, symptomatic, multiple myeloma: Analysis in 1937 patients (2013) Blood, 122, p. 1867. , abstr; Terpos, E., Christoulas, D., Kastritis, E., The chronic kidney disease epidemiology collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPICysC equations? (2013) Eur J Haematol, 91, pp. 347-355; Terpos, E., Katodritou, E., Tsiftsakis, E., Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration (2009) Haematologica, 94, pp. 372-379; Palumbo, A., Avet-Loiseau, H., Oliva, S., Revised international staging system for multiple myeloma: A report from international myeloma working group (2015) J Clin Oncol, 33, pp. 2863-2869; Srisawat, N., Hoste, E.E., Kellum, J.A., Modern classification of acute kidney injury (2010) Blood Purif, 29, pp. 300-307; Ando, M., Mori, J., Ohashi, K., A comparative assessment of the RIFLE, AKIN and conventionalcriteria for acute kidney injury after hematopoietic SCT (2010) Bone Marrow Transplant, 45, pp. 1427-1434; Shi, H., Zhang, W., Li, X., Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: S 15-year retrospective, single center, cohort study (2014) Leuk Lymphoma, 55, pp. 1076-1082; Leung, N., Gertz, M., Kyle, R.A., Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathyrelated kidney diseases (2012) Clin J Am Soc Nephrol, 7, pp. 1964-1968; Dimopoulos, M.A., Terpos, E., Renal insufficiency and failure (2010) Hematology Am Soc Hematol Educ Program 2010, pp. 431-436; Merlini, G., Palladini, G., Differential diagnosis of monoclonal gammopathy of undetermined significance (2012) Hematology Am Soc Hematol Educ Program 2012, pp. 595-603; Dimopoulos, M.A., Terpos, E., Chanan-Khan, A., Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the international myeloma working group (2010) J Clin Oncol, 28, pp. 4976-4984; Morabito, F., Gentile, M., Mazzone, C., Safety and efficacy of bortezomib-melphalan-prednisonethalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment (2011) Blood, 118, pp. 5759-5766; Dimopoulos, M.A., Roussou, M., Gkotzamanidou, M., The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma (2013) Leukemia, 27, pp. 423-429; Pönisch, W., Moll, B., Bourgeois, M., Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure (2013) J Cancer Res Clin Oncol, 139, pp. 1937-1946; Park, S., Han, B., Kim, K., Renal Insufficiency in newly-diagnosed multiple myeloma: Analysis according to International myeloma working group consensus statement (2014) Anticancer Res, 34, pp. 4299-4306; Ludwig, H., Rauch, E., Kuehr, T., Lenalidomide and dexamethasone for acute light chaininduced renal failure: A phase II study (2015) Haematologica, 100, pp. 385-391; Dimopoulos, M.A., Terpos, E., Roussou, M., Validation of criteria for renal response in patients with multiple myeloma (MM) who present with severe renal dysfunction (2013) Blood, 122, p. 3176. , abstr; Palumbo, A., Rajkumar, S.V., San Miguel, J.F., International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation (2014) J Clin Oncol, 32, pp. 587-600; MRC working party on leukaemia in adults: Analysis and management of renal failure in fourth MRC myelomatosis trial (1984) Br Med J, 288, pp. 1411-1416. , Clin Res Ed; Terpos, E., Morgan, G., Dimopoulos, M.A., International myeloma working group recommendations for the treatment of multiple myelomarelated bone disease (2013) J Clin Oncol, 31, pp. 2347-2357; Watkins, K.R., Rogers, J.E., Atkinson, B., Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency (2015) Support Care Cancer, 23, pp. 1657-1662; Sanders, P.W., Booker, B.B., Pathobiology of cast nephropathy from human Bence Jones proteins (1992) J Clin Invest, 89, pp. 630-639; Pozzi, C., Pasquali, S., Donini, U., Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: A review of 50 cases (1987) Clin Nephrol, 28, pp. 1-9. , Report of the Italien Renal Immunopathology Group; Zucchelli, P., Pasquali, S., Cagnoli, L., Controlled plasma exchange trial in acute renal failure due to multiple myeloma (1988) Kidney Int, 33, pp. 1175-1180; Johnson, W.J., Kyle, R.A., Pineda, A.A., Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy (1990) Arch Intern Med, 150, pp. 863-869; Clark, W.F., Stewart, A.K., Rock, G.A., Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial (2005) Ann Intern Med, 143, pp. 777-784; Burnette, B.L., Leung, N., Rajkumar, S.V., Renal improvement in myeloma with bortezomib plus plasma exchange (2011) N Engl J Med, 364, pp. 2365-2366; Yu, X., Gan, L., Wang, Z., Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: A meta-analysis (2015) Int J Clin Pharmacol Ther, 53, pp. 391-397; Hutchison, C.A., Heyne, N., Airia, P., Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis (2012) Nephrol Dial Transplant, 27, pp. 3823-3828; Heyne, N., Denecke, B., Guthoff, M., Extracorporeal light chain elimination: High cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury (2012) Ann Hematol, 91, pp. 729-735; Zannetti, B.A., Zamagni, E., Santostefano, M., Bortezomib-based therapy combined with high cutoff hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment (2015) Am J Hematol, 90, pp. 647-652; Torra, R., Blade, J., Cases, A., Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases (1995) Br J Haematol, 91, pp. 854-859; Irish, A.B., Winearls, C.G., Littlewood, T., Presentation and survival of patients with severe renal failure and myeloma (1997) QJM, 90, pp. 773-780; Gonsalves, W.I., Leung, N., Rajkumar, S.V., Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma (2015) Blood Cancer J, 5, p. e296; Cooper, E.H., Forbes, M.A., Crockson, R.A., Proximal renal tubular function in myelomatosis: Observations in the fourth medical research council trial (1984) J Clin Pathol, 37, pp. 852-858; Knudsen, L.M., Hjorth, M., Hippe, E., Renal failure in multiple myeloma: Reversibility and impact on the prognosis (2000) Eur J Haematol, 65, pp. 175-181; Dimopoulos, M.A., Richardson, P.G., Schlag, R., VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study (2009) J Clin Oncol, 27, pp. 6086-6093; Alexanian, R., Barlogie, B., Dixon, D., Renal failure in multiple myeloma. Pathogenesis and prognostic implications (1990) Arch Intern Med, 150, pp. 1693-1695; Blade, J., Fernández-Llama, P., Bosch, F., Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution (1998) Arch Intern Med, 158, pp. 1889-1893; Bayraktar, U.D., Warsch, S., Pereira, D., High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma (2011) Am J Hematol, 86, pp. 224-227; Kastritis, E., Anagnostopoulos, A., Roussou, M., Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents (2007) Haematologica, 92, pp. 546-549; Fakhouri, F., Guerraoui, H., Presne, C., Thalidomide in patients with multiple myeloma and renal failure (2004) Br J Haematol, 125, pp. 96-97; Tosi, P., Zamagni, E., Cellini, C., Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure (2004) Eur J Haematol, 73, pp. 98-103; Tosi, P., Zamagni, E., Tacchetti, P., Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosedmultiplemyeloma and renal insufficiency (2010) Biol Blood Marrow Transplant, 16, pp. 1115-1121; Niesvizky, R., Naib, T., Christos, P.J., Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-näive patients undergoing frontline lenalidomide and dexamethasone therapy (2007) Br J Haematol, 138, pp. 640-643; Dimopoulos, M., Alegre, A., Stadtmauer, E.A., The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function (2010) Cancer, 116, pp. 3807-3814; De La Rubia, J., Roig, M., Ibañez, A., Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: A Spanish multicenter retrospective study (2010) Eur J Haematol, 85, pp. 363-365; Dimopoulos, M.A., Christoulas, D., Roussou, M., Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: Dosing of lenalidomide according to renal function and effect on renal impairment (2010) Eur J Haematol, 85, pp. 1-5; Klein, U., Neben, K., Hielscher, T., Lenalidomide in combination with dexamethasone: Effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment (2011) Ann Hematol, 90, pp. 429-439; Zhou, D.B., Yu, L., Du, X., Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment (2015) Int J Hematol, 101, pp. 569-577; Dimopoulos, M.A., Cheung, M.C., Roussel, M., Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma (2015) Haematologica, , pii: haematol.2015.133629, (in press); Weisel, K.C., Dimopoulos, M.A., Cavo, M., Pomalidomide plus low-dose dexamethasone in patients with relapsed or relapsed and refractorymultiple myeloma and renal impairment: Analysis of patients from the phase 3b STRATUS trial (MM-010) (2014) Blood, 124, p. 4755. , abstr; Roussou, M., Kastritis, E., Christoulas, D., Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents (2010) Leuk Res, 34, pp. 1395-1397; Harris, E., Behrens, J., Samson, D., Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia (2003) Br J Haematol, 122, pp. 160-161; Dimopoulos, M.A., Palumbo, A., Attal, M., Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement (2011) Leukemia, 25, pp. 749-760; Dimopoulos, M.A., Leleu, X., Palumbo, A., Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) Leukemia, 28, pp. 1573-1585; Jagannath, S., Barlogie, B., Berenson, J.R., Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function (2005) Cancer, 103, pp. 1195-1200; San-Miguel, J.F., Richardson, P.G., Sonneveld, P., Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study (2008) Leukemia, 22, pp. 842-849; Blade, J., Sonneveld, P., San Miguel, J.F., Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patientswith renal function impairment (2008) Clin Lymphoma Myeloma, 8, pp. 352-355; Dimopoulos, M.A., Roussou, M., Gavriatopoulou, M., Reversibility of renal impairment in patients with multiple myeloma treated with bortezomibbased regimens: Identification of predictive factors (2009) Clin Lymphoma Myeloma, 9, pp. 302-306; Ludwig, H., Adam, Z., Hajek, R., Light chaininduced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study (2010) J Clin Oncol, 28, pp. 4635-4641; Morabito, F., Gentile, M., Ciolli, S., Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA (2010) Eur J Haematol, 84, pp. 223-228; Scheid, C., Sonneveld, P., Schmidt-Wolf, I.G., Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: A subgroup analysis from the HOVON-65/GMMG-HD4 trial (2014) Haematologica, 99, pp. 148-154; Dimopoulos, M.A., Roussou, M., Gavriatopoulou, M., Bortezomib-based triplets are associatedwith a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis (2016) Am J Hematol, , in press; Sonneveld, P., Salwender, H., Van Der Holt, B., Long term follow up of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib vs standard treatment in patients with multiple myeloma (2015) Blood, 126, p. 27. , abstr; Moreau, P., Pylypenko, H., Grosicki, S., Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY-3021 study (2015) Haematologica, 100, pp. e207-e210; Merz, M., Salwender, H., Haenel, M., Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: An interim analysis from the prospective GMMG-MM5 trial (2015) Haematologica, 100, pp. 964-969; Badros, A.Z., Vij, R., Martin, T., Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety (2013) Leukemia, 27, pp. 1707-1714; Dimopoulos, M.A., Moreau, P., Palumbo, A., Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomized, phase 3, open-label, multicenter study (2016) Lancet Oncol, 17, pp. 27-38; Moreau, P., Masszi, T., Grzasko, N., Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progressionfree survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): The phase 3 Tourmaline-MM1 study (2015) Blood, 126, p. 727. , abstr; San, M.J.F., Lahuerta, J.J., Garćia-Sanz, R., Are myeloma patients with renal failure candidates for autologous stem cell transplantation? (2000) Hematol J, 1, pp. 28-36; Badros, A., Barlogie, B., Siegel, E., Results of autologous stem cell transplant in multiple myeloma patients with renal failure (2001) Br J Haematol, 114, pp. 822-829; Lee, C.K., Zangari, M., Barlogie, B., Dialysisdependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant (2004) Bone Marrow Transplant, 33, pp. 823-828; Parikh, G.C., Amjad, A.I., Saliba, R.M., Autologous hematopoietic stem cell transplantation may reverse renal failure in patientswithmultiplemyeloma (2009) Biol Blood Marrow Transplant, 15, pp. 812-816; Breitkreutz, I., Heiss, C., Perne, A., Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure (2014) Bone Marrow Transplant, 49, pp. 1371-1375; Spitzer, T.R., Sykes, M., Tolkoff-Rubin, N., Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease (2011) Transplantation, 91, pp. 672-676